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Background: The metastasis of hematogenous cancer cells is associated with abnormal glycosylation such as sialyl
lewis antigens. Although the hepatitis B virus X protein (HBx) plays important role in liver disease, the precise function
of HBx on aberrant glycosylation for metastasis remains unclear.
Methods: The human hepatocellular carcinoma tissues, HBx transgenic mice and HBx-transfected cells were used to
check the correlation of expressions between HBx and Sialyl lewis antigen for cancer metastasis. To investigate whether
expression levels of glycosyltransferases induced in HBx-transfected cells are specifically associated with sialyl lewis A
(SLA) synthesis, which enhances metastasis by interaction of liver cancer cells with endothelial cells, ShRNA and siRNAs
targeting specific glycosyltransferases were used.
Results: HBx expression in liver cancer region of HCC is associated with the specific synthesis of SLA. Furthermore, the
SLA was specifically induced both in liver tissues from HBx-transgenic mice and in in vitro HBx-transfected cells.
HBx increased transcription levels and activities of α2-3 sialyltransferases (ST3Gal III), α1-3/4 fucosyltransferases III
and VII (FUT III and VII) genes, which were specific for SLA synthesis, allowing dramatic cell-cell adhesion for metastatic
potential. Interestingly, HBx specifically induced expression of N-acetylglucosamine-β1-3 galactosyltransferase V (β1-3GalT
5) gene associated with the initial synthesis of sialyl lewis A, but not β1-4GalT I. The β1-3GalT 5 shRNA suppressed SLA
expression by HBx, blocking the adhesion of HBx-transfected cells to the endothelial cells. Moreover, β1-3GalT 5 silencing
suppressed lung metastasis of HBx-transfected cells in in vivo lung metastasis system.
Conclusion: HBx targets the specific glycosyltransferases for the SLA synthesis and this process regulates hematogenous
cancer cell adhesion to endothelial cells for cancer metastasis.
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Metastasis consists of a series of sequential steps, such
as shedding of cells from a primary tumor into circulation,
survival of the cells in circulation, arrest in a new organ,
extravasation into the surrounding tissue, initiation and
maintenance of growth, and vascularization of the meta-
static tumor [1]. Furthermore, the adhesion of malignant
cells to the vascular endothelium is an important step for* Correspondence: chkimbio@skku.edu
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nant transformation is associated with abnormal glycosyla-
tion, resulting in the synthesis and expression of altered
carbohydrate determinants on protein or lipid [3]. Expres-
sion of carbohydrate determinants, such as SLA and sialyl
lewis X (SLX), is markedly enhanced in cancer cells [4,5].
Also, SLA and SLX are involved in E-selectin-mediated
adhesion of cancer cells to vascular endothelium, and these
determinants play important roles in the hematogenous
metastasis of cancer cells [4,6]. HBV induces acute and
chronic hepatitis, and is closely associated with the inci-
dence of human liver cancer. Among the four proteins that
originate from the HBV genome, HBx has been reportedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Moreover, HBx induces liver cancer in transgenic mice
[9,10]. Recently, we have found that HBx causes the pro-
gression of liver cancer through the reduced expression of
tumor suppressor PTEN [11]. Furthermore, we have re-
ported that the enhanced expression of MMP-9 is eventu-
ally associated with the invasive potential of liver cells [12].
Previous studies show that HBx is potentially associated
with hepatocellular carcinogenesis and invasion [11-14].
However, the precise function of HBx in the metastasis of
liver cancer remains unclear at this time. Moreover, al-
though HBV induces aberrant glycosylation-coupled hepa-
tocellular carcinogenesis [15], some questions remain as to
how the HBV functions on the aberrant glycosylation and
selectively occupies its specific glycosylation targets for
carcinogenesis and malignant metastasis.
In this study, we identified a relationship between HBx
and SLX/A in liver cancer patients, and investigated
whether HBx induces the expression of SLX/A in liver
cells and HBx-transgenic mice. SLA-synthetic glycosyl-
transferase genes were transcriptionally up-regulated
by HBx transfection in human normal Chang cells in vitro.
Additionally, RNA-interference mediated depletion of
SLA-synthesis machinery reduced HBx-dependent ad-
hesion of liver cancer cells to endothelial cells and tumor
metastasis in vivo. Together, it was demonstrated that
HBx for metastatic potential is to select the specific ex-
pression of A type among sialyl lewis antigens, and finally,




Human hepatocellular carcinomas (n = 11) used in this
study were obtained from the department of Pathology,
Yeungnam University Hospital. The protocols outlined
in the following text were approved by the Ethics Com-
mittee of Yeungnam University Hospital.
Animals
Paraffin blocks of liver tissues from transgenic mice car-
rying the HBx gene at the age of 3, 9 and 13 months
used this study were obtained from Dr. Yu [10].
Cell culture and transfection
Chang cells (ATCC number CCL-13), a human liver cell
line and HBx-transfected cells were maintained using
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS) at 37°C in a
humidified 5% CO2 incubator. To investigate the rela-
tionship between HBx and carbohydrate ligand expression,
the 465-bp cDNA encoding the open reading frame for
HBx was inserted into the pcDNA3 expression vector at
the HindIII/KpnI sites. The cells were used for stabletransfection with HBx using LipofectAMINE (Invitrogen)
reagent following the manufacturer’s instructions. Trans-
fected cells were then selected using cell culture medium
containing 500 μg/ml G418 sulfate. Human umbilical vein
endothelial cells (HUVECs) were obtained from Cambrex
Bio Science (MD, USA), and were cultured in sterile endo-
thelial growth medium (EGM-2, Cambrex Bio Science)
and were maintained at 37°C in a humidified 5% CO2 in-
cubator. Passages 5 to 8 of HUVECs were used in mono-
layer cell adhesion assay.Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA from each cell was isolated using the Coresol
reagent (Corebio. Co., Seoul, Korea), and the cDNAs
were synthesized by reverse transcriptase with an oligo
dT-adaptor primer from a RNA PCR kit (Bioneer, Daejon,
Korea) according to the manufacturer’s recommended
protocol. The cDNA was amplified by PCR with primers,
as shown in Additional file 1: Table S1. The use of equal
amounts of mRNA in the RT-PCR assays was confirmed
by analyzing the expression levels of β-actin. The PCR
products were separated by gel electrophoresis on 2%
agarose containing ethidium bromide with 1× TAE buffer.Immunohistochemistry
The liver tissues of non-transgenic mice (C57BL/6) and
HBx-transgenic mice, normal liver tissues and liver cancer
tissues of HBV-non infected and HBV-infected patients
were fixed in 3.7% formalin and embedded in paraffin, and
were then cut into 4 μm serial sections. The sections and
HBx-transfected cells were immunostained with HBx,
SLX and SLA antibodies, visualized with Dako EnVision
kit (Dako, USA), and counterstained with hematoxylin.Monolayer cell adhesion assay
HUVECs were confluently cultured in 12 well plate and
stimulated with or without TNF-α (10 ng/ml) for 8 h.
Chang, Chang-pcDNA and Chang-pcDNA-HBx cells (5 ×
105cells/well) stained with DAPI were added on a monolayer
culture of TNF-α-unstimulated or stimulated HUVECs, in-
cubated for 20 min at 37°C with rotation at 60 rpm in shak-
ing incubator, and washed to exclude non-specific cell to
cell interaction. The attached cells were visualized using a
microscope. To check the antibody-mediated inhibition of
cell adhesion, the TNF-α-stimulated HUVECs were incu-
bated with E-selectin (BD Biosciences) antibodies for 4 h at
37°C in humidified CO2 incubator, and each cell was then
added to monolayer-cultured TNF-α-stimulated HUVECs.
To block cell adhesion by SLA or SLX antibody, each cell
was incubated with the antibody for 1 h and was then added
to the TNF-α-induced HUVECs.
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The surface expression of SLX and SLA on each cell type
was analyzed by FACS Calibur (Becton Dickinson, USA)
using mouse anti- SLX and SLA after 24 h culture. The
expression of SLX and SLA was analyzed by staining cells
with monoclonal anti- SLX and SLA antibodies and then
with goat anti-mouse IgM and IgG-FITC. The levels of
antigen synthesized on the cell surface were expressed as
the mean fluorescence intensity (MFI). Each experiment
was repeated several times and the values represent a
mean of two independent determinations.
Preparation and transfection of small interfering RNA
(siRNA) and small hairpin RNA (shRNA)
Each siRNA duplex was designed to target the coding
sequence of human ST3Gal III, FUT III and VII mRNA,
and plant chlorophyll a/b-binding protein mRNA was used
as a negative control, and synthesized by Bioneer corp.
(Daejeon, Korea). The target sequences of ST3Gal III, FUT
III and VII siRNAs are 5′-CCUGCUGAAUUAGCCAC
CAdTdT-3′, 5′-CACACUCAGGUGACCUACAdTdT-3′
and 5′-CCCUGAACAAAUCUUGGGUdTdT-3′ respect-
ively. HBx-transfected cells were co-transfected with ST3Gal
III, FUT III, VII siRNAs and negative control siRNA re-
spectively by using LipofectAMINE (Invitrogen) according
to the manufacturer’s instructions. One day after transfec-
tion, the cells were used for experiments. In order to silence
with β-1, 3 GalT 5 gene, three pairs of oligonucleotides were
designed by the siRNA target finder (Ambion). Different
regions of human β-1,3 GalT 5 gene were annealed and
cloned in the pSilencer™ 3.1-H1 puro expression vector
(Ambion, Austin, TX) digested with HindIII/BamHI double
digested pMEHMpuro. Three target sequences were; (1)







1 M (63) - - -
2 M (57) HBV + -
3 M (55) HBV + -
4 M (44) HBV + +
5 M (55) HBV + +
6 M (62) HBV + +
7 F (56) HBV + +
8 M (59) - - -
9 M (46) HBV + +
10 M (62) - - -
11 M (49) - - -
Results of SLX and SLA expression detected by immunohistochemistry are given ac
staining; +, weak staining (<5% hepatocytes); ++, strong staining (>5% ~ <20% hep
no detection; ×, no expression; O, expression.TCAGTAAATCT, (3) CTCGAAAGGCTGAACATCAGA
TTGG. After transfection with shRNA vectors using
the Welfect method (Welgene, Daegu, Korea), cells
were selected by puromycin (250 ng/mL) and used in
the experiments.
Reporter plasmids and luciferase assay
For preparation of human ST3Gal III, FUT III, VII and
β-1,3 GalT 5 promoters, transcriptional start points of
each gene were identified and the 5′-flanking sequence
was obtained. PCR amplification from the genomic DNA
of HBx-transfected Chang cells was performed with
EF-Taq polymerase (SolGent, Seoul, Korea) using primers,
as shown in Additional file 1: Table S2. The amplified frag-
ments of each gene were sequenced using pT7Blue(R) T-
vector (Novagen) and were inserted into the pGL3-Basic
vector (Promega, Madison, WI) digested with each restric-
tion enzyme. After co-transfection with each-luciferase re-
porter plasmid and β-galactosidase reporter plasmid, cells
were rinsed in PBS, and lysed in Luciferase Lysis Buffer
(Promega). Luciferase activities were measured using
the Luciferase assay system (Promega) and Luminoskan
Ascent (Thermo Labsystems, Helsinki, Finland). Luciferase
activity was normalized with the β-galactosidase activity in
each cell lysate. Data were represented as the mean from
three independent experiments.
Immunofluorescence microscopy
To confirm the enhanced expression of carbohydrate
ligands on the liver cell surface by HBx, Chang cells
and HBx-transfected cells were seeded at a sub-confluent
density on sterile coverslips in 6-well tissue culture plates.
After incubating the attached cells in DMEM containing
















cording to the distribution of positive hepatocytes in cancer region: −, no
atocytes); +++, very strong staining (>20% hepatocytes). M, male; F, female; -,
Figure 1 The expression of SLA in cancer region of HBx-expressed HCC patients. Normal liver tissues and liver cancer tissues of HBV-non
infected and HBV-infected patients were fixed in 3.7% formalin and embedded in paraffin, and then they were cut into 4 μm serial sections.
The sections were immunostained with HBx, SLX and SLA antibodies, visualized with Dako EnVision kit (Dako, USA), and counterstained with
hematoxylin. (A) Dark brown staining indicates the expression of HBx, SLX and SLA in the cancer region of HBV-non infected or HBV-infected
patients. (B) SLA expression in cancer region (CR) and normal region (NR) of HCC patients is stained as dark brown.
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blocked with 5% bovine serum albumin-containing PBS
for 30 min at room temperature with gentle rocking.
Thereafter, a solution of SLX and SLA antibodies was
flooded over the cells and the cultures were incubated
at 4°C overnight. After washing with PBS, the cells were fur-
ther incubated with FITC-conjugated goat anti-mouse IgM
and IgG for 1 h at room temperature, followed by washing
with PBS, and were then analyzed using fluorescence mi-
croscopy. The pre-absorbed primary antibody or the sec-
ondary antibody alone was also applied as a negative control
experiment.Lung metastasis assay
Chang-HBx cells, pSilencer vector-transfected Chang-HBx
cells and β-1,3Gal T5 shRNA-tranfected Chang-HBx cells
(5 × 105) in 10 μl PBS were injected into the tail vein of 8-
week-old female BALB/c nude mice (n = 6-8). The mice
were cared for in accordance with the national and inter-
nationals rules of Korea for animal studies. 35 days after
injection with cells, the mice were euthanized, and lungs
from each mice were isolated. The isolated lung tissues
were fixed in 10% formalin and embedded in paraffin, and
were then stained with hematoxylin and eosin prior to
determination.
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The relationship between HBx and SLA in HCC patients
An increased expression of SLX and SLA structures in
various malignancies and in metastatic lesions has been
well documented [4,5,16,17]. To determine whether HBx
expression in liver cancer is associated with SLX/A ex-
pression, we performed immunohistochemistry using liver
tissues obtained from 11 HCC patients (10 males and 1 fe-
male) between the ages of 44 and 63. As shown in Table 1
and Figure1A, although SLX was highly expressed in liver
cancer tissues, HBx expression in HBV-infected HCC was
not associated with its expression. However, as shown in
Table 1 and Figure 1A and B, HBx expression in the
cancer region of HBV-infected HCC was more related
to SLA expression than that of HBV-uninfected HCC
and HBx no-expression in HBV-infected HCC, except
in the case of patient No. 2. Moreover, as shown in
Figure 1B, SLA expression was increased in the cancer
region of HCC compared to the normal region. These
results suggest that HBx might induce the formation of
SLA in the cancer region.Figure 2 The expression of SLA antigen in HBx-transgenic mice. (A) T
mice were fixed inn 3.7% formalin and embedded in paraffin, and were then
HBx, SLX and SLA antibodies, visualized with Dako EnVision kit (Dako, US
immunostained without the primary antibody. (B) Total proteins (30 μg)
was performed with the indicated antibodies.The enhanced expression of SLA in HBx-transgenic mice
Previously, Yu group has reported that HCC frequently
occurred in HBx-transgenic mice [9]. Furthermore, several
researchers have reported HBx function in hepatocarcino-
genesis using these mice. Thus, we examined whether HBx
is associated with the expression of sialyl lewis antigens in
HBx-transgenic mice. The dysplastic liver region of HBx
transgenic mice at the age of 13 months showed small
neoplastic nodules and grossly identified HCCs, which
was consistent with the results of a previous report
[10]. As shown in Figure 2, in liver tissue from 9 and 13
month old HBx-transgenic mice, H&E staining showed
mild to severe hepatic necrosis, fatty change, mild to mod-
erate chronic hepatitis and cytoplasmic vacuolation, com-
pared to normal mice and 3 month old HBx-transgenic
mice. Furthermore, liver tissue from 13 month old HBx-
transgenic mice showed that the nuclei/cytoplasm ratio
was increased. Immunostaining against HBx antibody
showed that HBx was only expressed in HBx-transgenic
mice (Figure 2). Interestingly, SLA expression was highly
detected in liver tissue from 13 month old HBx-transgeniche liver tissues of non-transgenic mice (C57BL/6) and HBx-transgenic
cut into 4 μm serial sections. The serial sections were immunostained with
A), and counterstained with hematoxylin. Negative controls were
from each liver tissue were isolated and immunoblotting analysis
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from normal or HBx-transgenic mice. These results sug-
gest that HBx is associated with SLA expression in liver
cancer.
Enhanced expressions and transcriptional activities of α2-3
sialyltransferases and α1-3/4 fucosyltransferases by HBx
Fucosyltransferases and α2-3 sialyltransferases are required
for SLX and SLA synthesis (Additional file 1: Figure S1)
[3]. Thus, we checked the expression patterns of α2-3
sialyltransferases (ST3Gal I-VI) and α1-3/4 fucosyltrans-
ferases (FUT III-VII) in HBx-transfected cells. As shown in
Additional file 1: Figure S2A, HBx obviously up-regulated
mRNA expression of ST3Gal III, one of six α2-3 sialyl-
transferase isoenzymes. Among five fucosyltransferases
(FUT III-VII), HBx markedly increase mRNA levels of
FUT III and VII genes (Additional file 1: Figure S2A).
As HBx regulates mRNA levels of ST3Gal III, FUT III
and VII genes, the transcription activities of these genes
were assessed using the luciferase reporter assay system
in pcDNA and HBx-transfected Chang cells. As shown
in Additional file 1: Figure S1B, the transcriptional ac-
tivities of the ST3Gal III, FUT III and VII promoters
were significantly increased in HBx-transfected Chang
cells, as compared with the control (pcDNA-transfectedFigure 3 The increase of SLA determinant in HBx-transfected cells an
(A) The cells were fixed, and then immunostained with SLA and SLX antibodies
(B) Chang, Chang-pcDNA and Chang-pcDNA-HBx cells (5 × 105 cells/well
incubated for 20 min at 37°C with rotation at 60 rpm in a shaking incubator. T
antibody-mediated inhibition of cell adhesion, the TNF-α-stimulated HUVECs w
CO2 incubator, and each cell was then added to monolayer-cultured TNF-α-st
each of cells was incubated with the antibody for 1 h and added to the TNF-Chang cells). These results suggest that HBx modulates
transcription levels of ST3Gal III, FUT III and VII
genes for SLX and SLA synthesis.
The induction of SLA in HBx-transfected cells and
HBx-transfected cell adhesion to endothelial cells
SLX and SLA determinants are synthesized by α2-3
sialyltransferases, including ST3Gal I-VI and α1-3/4
fucosyltransferases, such as FUT III-VII, in several types of
cancer cells [18-23]. We further investigated whether HBx
results in the stimulation of SLX and SLA expression in
liver cells. As shown in Figure 3A, immunostaining against
SLA clearly showed an increase in HBx-transfected Chang
cells compared to Chang and Chang pcDNA cells, but not
SLX. This result indicates that HBx induces SLA expres-
sion. SLA or SLX determinant synthesized on surface of
cancer cells and E-selectin expressed on endothelial cells
induced by inflammatory stimulus such as TNF-α, IL-1α
or IL-1β are required for hematogenous metastasis because
the adhesion of malignant cells to the vascular endothe-
lium is an important step for extravasation into target tis-
sues of a new organ [4-6]. Thus, we investigated whether
HBx-transfected cells are attached to TNF-α-stimulated
endothelial cells. As shown in Figure 3B, the adhesion of
Chang-pcDNA-HBx cells to TNF-α-treated endotheliald the adhesion of HBx-transfected cells to endothelial cells.
. The immunostained cells were analyzed using a fluorescence microscope.
) were added on TNF-α-unstimulated or stimulated HUVECs, and were
he attached cells were visualized using a microscope. (C) To check the
ere incubated with E-selectin antibody for 4 h at 37°C in a humidified
imulated HUVECs. To block cell adhesion by SLA or SLX-specific antibody,
α-induced HUVECs.
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Chang, Chang-pcDNA and Chang-pcDNA-HBx cells to
TNF-α-untreated endothelial cells, as well as Chang and
Chang-pcDNA cells to TNF-α-activated endothelial cells.
We further checked whether the SLA expression on HBx-
transfected cells and E-selectin expressed on TNF-α-
stimulated endothelial cells is closely associated with
cancer cell to endothelial cell interactions for metastatic
potential, using antibodies against SLX/A and E-selectin.
As shown in Figure 3C, the enhanced adhesion of Chang-
pcDNA-HBx cells to TNF-α-treated endothelial cells is
markedly inhibited by treatment with anti-SLA and E-
selectin antibodies, respectively, but not by treatment with
anti-SLX antibody. These results clearly indicate that SLA
expressed by HBx on liver cancer cells is critical for cell-
to-cell adhesion by binding it to E-selectin expressed on
TNF-α-stimulated endothelial cells.
The inhibition of SLA expression in HBx-transfected cells
and HBx-tranfected cell adhesion to endothelial cells by
ST3Gal III, FUT III and FUT VII siRNAs
To clarify whether induction of ST3 Gal III, FUT III and
FUT VII expression by HBx is essential for SLA expressionFigure 4 The inhibition of SLA expression in HBx-transfected cells an
FUT III and FUT VII siRNAs. (A) Each cell was co-transfected with ST3Gal
Total RNA from these cells was isolated. The mRNA expression of ST3Gal
indicated in Table 1. β-actin was included as an internal control. (B) To check w
by the siRNAs against ST3Gal III, FUT III and FUT VII genes, the expression was e
Fluorescence histograms of a representative experiment indicate the baseline e
the x-axis gives fluorescence intensity. (C) Each cell was co-transfected with ST3
Each cell was added on TNF-α-stimulated HUVECs, and was incubated for 20 m
cells were visualized using a microscope, as described in Materials and Methodin liver cancer cells, the expression of these enzymes was
depleted using RNA-interference strategy in HBx-expressing
cells. As shown in Figure 4A, the increased transcription of
ST3Gal III, FUT III and FUT VII genes in HBx-tansfected
cells was inhibited by the transient transfection of ST3Gal
III, FUT III and FUT VII siRNAs, respectively. Furthermore,
as shown in Figure 4B, silalyl lewis A expression induced in
HBx-transfected cells was diminished by the siRNAs against
ST3Gal III, FUT III and FUT VII genes, respectively, as
evidenced by immunofluorescence staining and flow cy-
tometric analysis. These results suggest that the induc-
tion of ST3Gal III, FUT III and FUT VII expression by
HBx is essential for the production of SLA determinant
in liver cancer.
We further investigated whether the enhanced adhe-
sion of Chang-pcDNA-HBx cells to TNF-α-stimulated
endothelial cells is obstructed using siRNAs against
ST3Gal III, FUT III and FUT VII genes. As shown in
Figure 4C, the increased adhesion of Chang-pcDNA-HBx
cells to TNF-α-stimulated endothelial cells was clearly
suppressed by the siRNAs against ST3Gal III, FUT III
and FUT VII genes, but not negative siRNA. These re-
sults indicate that SLA determinant, synthesized throughd HBx-tranfected cell adhesion to endothelial cells by ST3Gal III,
III, FUT III and VII siRNAs, as well as negative control siRNA, respectively.
III, FUT III and VII were detected by RT-PCR, using primers which are
hether SLA expression induced in HBx-transfected cells was suppressed
xamined using flow cytometric analysis and immunofluorescent staining.
xpression of SLA. The y-axis gives the percentage of positive cells (counts);
Gal III, FUT III and VII siRNAs and negative control siRNA (N.C.), respectively.
in at 37°C with rotation at 60 rpm in a shaking incubator. The attached
s.
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VII by HBx in liver cells, binds to E-selectin induced by
inflammatory cytokines in endothelial cells.
The suppression of cell adhesion to endothelial cells
and lung metastasis in HBx-transfected cells with β1,
3-galactosyltransferase shRNAs
As shown in Additional file 1: Figure S1, at the initial step
of the biosynthesis of SLA antigen, N-acetylglucosamine-
β1-3 galactosyltransferase V (β1-3Gal-T 5) transfers
galactose (Gal) to N-acetylglucosamine (GlcNac) with
1-3-linkage. This restricted distribution of Lewis type
1 antigens has been considered to result from the limited
expression of β1-3Gal-T 5, which synthesizes the type 1
structure [24]. On the other hand, for the generation of
SLX antigen, N-acetylglucosamine-β1-4 galactosyltransfer-
ase I (β1-4Gal-T I) catalyzes the addition of UDP-galactose
to terminal N-acetylglucosamine with 1-4-linkage for the
type 2 structure. [25]. Thus, we examined whether N-acet-
ylglucosamine-β1-3/4 galactosyltransferases is regulated by
HBx. Interestingly, HBx clearly induced the expression of
β1-3Gal-T 5, but not β1-4Gal-T I (Figure 5A). Next, the
transcription activity of β1-3Gal-T 5 was determined using
a luciferase reporter assay system in pcDNA and HBx-
transfected Chang cells. As shown in Figure 5B, the activity
of the β1-3Gal-T 5 promoter was significantly increased
in HBx-transfected cells compared to pcDNA-transfected
cells. We further investigated whether SLA expression in
HBx-transfected cells and the enhanced adhesion of
Chang-pcDNA-HBx cells to TNF-α-stimulated endothelial
cells are inhibited using shRNA against the β1-3Gal-T 5
gene. As shown in Figures 5C and D, the shRNA-1 and 2
against β1-3Gal-T 5 gene clearly suppressed β1-3Gal-T 5
mRNA and SLA expression in HBx-transfected cells.
Furthermore, the increased adhesion of Chang-pcDNA-
HBx cells to TNF-α-stimulated endothelial cells was
clearly inhibited by the shRNA against β1-3Gal-T 5
gene (Figure 5E). Based on the suppressed adhesion of
HBx-transfected cells to endothelial cells by β1-3Gal-T 5
shRNA, we further investigated whether the silencing of
β1-3Gal-T 5 expression suppresses lung metastasis of
HBx-transfected cells. As shown in the histologic re-
sults, micrometastatic lesions of lung isolated from
HBx-transfected cells carrying β1-3Gal-T 5 shRNA-1
and 2 were dramatically reduced compared to those of
HBx-transfected cells with and without negative con-
trol shRNA (Figure 5F). These results strongly suggest
that the induction of β1-3Gal-T 5 expression by HBx,
the first step of the synthesis of SLA, is induced by
HBx for liver cancer metastatic potential.
Discussion
SLA has been shown to be expressed in cancer cells de-
rived from the digestive organs, including colon, rectum,pancreas and biliary tract. Furthermore, SLX has been
reported to be highly expressed in breast, ovarian and
pulmonary cancer cells [3]. Moreover, in serum, the SLX
levels in patients with hepatocellular carcinoma were
significantly higher than those of normal controls as well
as those with benign liver cirrhosis [26]. Several studies
indicated that SLX expression might be associated with
hepatocellular carcinoma [27-29]. It has been reported
that glycan-related gene expression related to the synthesis
of N-glycan and glycolipids, particularly the sialyl Lewis
antigen was induced in human metastatic hepatocellular
carcinoma cells [30]. The induction of these carbohydrate
antigens in some cancers is considered as risk factor for
hematogenous metastasis. In this study, our results also
showed that SLX expression in cancer regions of HCC
patients was higher compared to non-cancer regions,
except in 3 cases, in which SLX was also highly expressed
in non-cancer regions. However, HBV infection and HBx
expression in HCC patients was not correlated with SLX
expression in cancer regions of HCC patients. Whereas,
HBx expression in cancer regions of HBV-infected HCC
was associated with SLA expression compared to HBV-
uninfected HCC and HBx no-expression in HBV-infected
HCC. Thus, we further investigated whether HBx expres-
sion lead the increased expression of sialyl lewis carbohy-
drate antigens in the liver cells and transgenic mice. Our
results found that HBx had an effect on the formation of
SLA determinant using HBx-transfected cells and HBx-
transgenic mice.
Sialylated carbohydrate antigens, such as SLX and SLA,
are divided into type 1 chain (Galβ1-3GlcNAc-R) and type
2 chain (Galβ1-4GlcNAc-R). The sequential addition of
galactose (Gal), sialic acid (Sia) and fucose (Fuc) to N-
acetylglucosamine (GlcNac) by glycosyltransferases is
required for the biosynthesis of SLX and SLA. First of all,
N-acetylglucosamine-β1-3 or β1-4 galactosyltransferase
transfers a galactose to an N-acetylglucosamine with 1–3
or 1-4-linkage, resulting in the synthesis of type 1 chain or
type 2 chain, and then galactose-α2-3 sialyltransferase
transfers a sialic acid to the Gal residue of the type 1 or 2
chain with an 2–3 linkage. Finally, α1-4/3 fucosyltransferase
transfers a fucose to the GlcNAc residue of the sialylated-
type 1 or 2 chain with an 1-4/3 linkage to complete the
synthesis of Siaα2-3Galβ1-3/4[Fucα1-4/3]GlcNAc struc-
ture for SLA or X [4,5,24]. Previous studies have indicated
that α2-3 sialyltransferases (ST3Gal I-VI) and α1-3/4
fucosyltransferases (FUT III-VII) were increased for the syn-
thesis of SLX and SLA determinant in various tumors. Thus,
we examined whether HBx modulates the transcription of
α2-3 sialyltransferase, α1-3/4 fucosyltransferase genes and
N-acetylglucosamine-β1-3/4 galactosyltransferases. Our
results showed that the transcriptional expressions and
activities of ST3Gal III, FUT III and FUT VII genes were
markedly induced by HBx in Chang cells. Moreover, to
Figure 5 (See legend on next page.)
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Figure 5 The inhibition of cell adhesion to endothelial cells and metastasis through the suppression of SLA synthesis in HBx-transfected
cells by β1,3-galactosyltransferase shRNA. (A) Total RNA from each cell was isolated using the Trizol reagent. The mRNA expressions of β1-3 and 4
galactosyltransferase genes were detected by RT-PCR using the primers indicated in Table 1. β-Actin was included as an internal control.
(B) After transfection with β1-3Gal-T 5 promoter, luciferase activity from the cells was analyzed as described in Materials and Methods.
Relative luciferase activity was normalized with the activity of pCMVβ-gal plasmid. (C) Each cell was transfected with the shRNA-1 and 2
against β1-3Gal-T 5 gene. Total RNA from these cells was isolated. The mRNA expression of β1-3Gal-T 5 gene was detected by RT-PCR
using the primers indicated in Table 1. β-Actin was included as an internal control. (D) To check whether silalyl lewis A expression induced
in HBx-transfected cells was suppressed by the shRNAs against β1-3Gal-T 5 gene, we examined this using flow cytometric analysis. Fluorescence histograms
of a representative experiment indicate the baseline expression of SLA. The y-axis gives the percentage of positive cells (counts); the x-axis
gives fluorescence intensity. (E) Each cell was transfected with the shRNA against β1-3Gal-T 5 gene. Each cell was added on TNF-α-stimulated
HUVECs, and was incubated for 20 min at 37°C with rotation at 60 rpm in a shaking incubator. The attached cells were then visualized using a
microscope. (F) Hematoxylin and eosin staining of the lungs. The stained sections of the lungs were photographed at 40× magnification. M,
metastatic nodule; N, normal.
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liver cancer cells through the induction of ST3Gal III,
FUT III and FUT VII expression, the siRNAs against
ST3Gal III, FUT III and FUT VII genes were used in HBx-
transfecte cells. Our study indicated that silalyl lewis A
expression induced in HBx-transfected cells was dimin-
ished by the siRNAs against ST3Gal III, FUT III and
FUT VII genes, respectively. These results suggest that
the HBx-induced sialyltransferase and fucosyltransferase
expression lead to the synthesis of SLA determinant in
HBx-tansfected cells. In addition to transcriptional studies,
our previous papers have shown that HBx activated AKT
signaling through the down-regulation of PTEN expres-
sion [11], and regulated the expression and transcriptional
regulation of MMP-9 by the activation of AP-1 and NF-κB
via ERKs and PI-3 K-AKT pathways [12]. Promoters of
ST3Gal III, FUT III, FUT VII and β-1,3 GalT5 related to
synthesis of sialyl lewis A also contain AP-1 and NF-κB
transcriptional factors as confirmed by Transcription
Element Search System to predict the possible transcrip-
tion factor binding sites in each promoter region (data not
shown). However, the precise transcriptional regulations
of these genes by HBx have not been characterized in the
present study. These issues will be focused on our further
study.
It has been well known that interactions between
endothelial selectins and cancer cells regulate metastasis
and E-selctin contributes to the adhesion of cancer cells to
endothelial cells by interacting with SLX and SLA for
hematogeneous metastasis. Furthermore, elevated levels of
serum E-selectin in patients bearing SLX- and SLA-
positive tumors has been shown to predict a high risk
for developing metastasis. A previous report indicated
that E-selectin expression is quite low in resting endo-
thelial cells [3,31]. However, E-selectin expression at
the surface of endothelial cells is induced by tumor-
derived IL-1α and monocyte-induced IL-1β in inflamma-
tory metastatic sites [3,32,33]. Furthermore, inflammation
can play a regulatory role in cancer progression and me-
tastasis. Metastatic tumor cells entering the liver trigger aproinflammatory response involving Kupffer cell-mediated
release of TNF-α and the up-regulation of E-selectin in
vascular endothelial cells [34]. In this study, we confirmed
the adhesion of HBx-transfected cells to TNF-α-stimulated
vascular endothelial cells using a monolayer cell adhesion
assay. To further clarify whether the interaction of SLA on
HBx-transfected cells with E-selectin on TNF-α-induced
endothelial cells is involved in HBx-transfected cell adhe-
sion to endothelial cells stimulated by TNF-α, specific anti-
bodies against SLX, SLA and E-selectin were used. Our
data clearly indicated that treatment of HBx-transfected
cells with SLA antibody, but not with SLX antibody, di-
minished cell to cell adhesion. Our previous data showed
that HBx induced SLA expression in liver cells through the
up-regulation of ST3Gal III, FUT III and FUT VII expres-
sion, Thus, we also checked whether the suppression of
SLA synthesis in HBx-transfected cells by ST3Gal III, FUT
III and FUT VII siRNAs, respectively, is associated with
the inhibition of HBx-transfected cell adhesion to TNF-α-
treated endothelial cells. The enhanced adhesion of HBx-
transfected cells to TNF-α-stimulated endothelial cells was
clearly decreased by the siRNAs against ST3Gal III, FUT
III and FUT VII genes. These results indicate that SLA
determinant synthesized by HBx-induced expression of
ST3Gal III, FUT III and FUT VII in liver cells binds to E-
selectin induced by TNF-α in endothelial cells, suggesting
metastasis of HBV-infected primary liver cancer.
Our data clearly showed that the enhancement of SLA
determinant in HBx-transfected cells was associated with
the induction of ST3Gal III, FUT III and FUT VII ex-
pression. However, several reports demonstrate that the
synthesis of SLX antigen is induced by the expression of
ST3Gal III, FUT III and FUT VII genes in various tu-
mors [3,4]. We questioned why the expression of SLA
but not SLX is induced by HBx in liver cells, and initially
assumed that the expression of β1-3 galactosyltransferase,
which transfers a galactose to an N-acetylglucosamine
with 1-3-linkage for the synthesis of SLA antigen, is in-
creased by HBx. Interestingly, our results showed that
HBx markedly induced β1-3 galactosyltransferase expression
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scriptional activity of β1-3 galactosyltransferase mRNA
was also increased in HBx-transfected cells. Furthermore,
the β1-3 galactosyltransferase shRNA suppressed SLA
antigen expressed by HBx in liver cells, and blocked the
adhesion of HBx-transfected cells to TNF-α-stimulated
endothelial cells. In the tumor metastasis assay, β1-3
galactosyltransferase shRNA significantly inhibited the
metastasis of the tail vein-injected HBx-transfected cells to
the lung in mice. Based on these findings, HBx increases
SLA determinant by inducing β1-3 galactosyltransferase
expression, resulting in liver cancer metastasis.
In conclusion, and as illustrated by Additional file 1:
Figure S3, the crucial step for the extravasation of cancer
metastasis is associated with the attachment of hematogenous
cancer cells to the blood vessel endothelium. In this
study, we demonstrate that HBV prefers the A type spe-
cific glycosyltransferases for the SLA synthesis in liver
cancer, and that the synthesized SLA further interacts with
E-selectin on endothelial cells. This process is the final
destination of the hematogenous cancer cell-involved viral
occupation to the host. Furthermore, we expect that the
relationship between HBx expression and sialyl lewis A
synthesis might be a clue of prognosis in malignancy of
HBV-infected liver cancer patients. In addition, the inhib-
ition of sialyl lewis A synthesis might be a therapeutic
avenue for the enhanced HBx expression in HBV-infected
liver cancer patients.
Additional file
Additional file 1 Table S1. The sequences of primers used in this
study. Table S2. The sequences of primers for constructions of each
promoter. Figure S1. The structure of SLA and SLX. For SLA synthesis,
N-acetylglucosamine-β1-3 galactosyltransferase (β1-3Gal-T 5) transfers a
galactose (Gal) to an N-acetylglucosamine (GlcNac) with 1-3-linkage,
resulting in the synthesis of type 1 chain, and then galactose-α2-3
sialyltransferase transfers a sialic acid (Sia) to the Gal residue of the type
1 with an 2-3 linkage. Finally, α1-4/3 fucosyltransferase transfers a
fucose (Fuc) to the GlcNAc residue of the sialylated-type 1 with an 1-4
linkage to complete the synthesis of Siaα2-3Galβ1-3[Fucα1-4]GlcNAc
structure. However, if N-acetylglucosamine-β1-4 galactosyltransferase I
(β1-4Gal-T I) catalyzes the addition of UDP-galactose to terminal
N-acetylglucosamine with 1-4-linkage, resulting in the synthesis of type
2 chain, continuously, galactose-α2-3 sialyltransferase transfers a sialic
acid to the Gal residue of the type 2 chain with an 2-3 linkage. Finally,
α1-4/3 fucosyltransferase transfers a fucose to the GlcNAc residue of
the sialylated-type 2 chain with an 1-3 linkage to complete the synthesis of
Siaα2-3Galβ1-4[Fucα1-3]GlcNAc structure. Figure S2. The enhanced expression
and promoter activity of ST3Gal III, FUT III and VII genes in HBx-transfected cells.
(A) Total RNA from each cell was isolated using the Trizol reagent. The mRNA
expression of α2-3 sialyltransferases and α1-3/4 fucosyltransferases genes was
detected by RT-PCR using primers indicated in Table 1. β-actin was included as
an internal control. 1, Chang; 2, Chang pcDNA; 3, Chang pcDNA-HBx. (B) After
transfection with each promoter, luciferase activity from the cells was analysed
as described in Materials and Methods. Relative luciferase activity was
normalized with the activity of pCMVβ-gal plasmid.
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